ESC/EAS Guidelines for the management of dyslipidaemias

被引:69
作者
Reiner, Zeljko [1 ]
Catapano, Alberico L. [2 ]
De Backer, Guy
Graham, Ian
Taskinen, Marja-Riitta
Wiklund, Olov
Agewall, Stefan
Alegria, Eduardo
Chapman, M. John
Durrington, Paul
Erdine, Serap
Halcox, Julian
Hobbs, Richard
Kjekshus, John
Filardi, Pasquale Perrone
Riccardi, Gabriele
Storey, Robert F.
Wood, David
机构
[1] Univ Zagreb, Sch Med, Univ Hosp Ctr Zagreb, Zagreb 10000, Croatia
[2] Univ Milan, Dept Pharmacol Sci, I-20133 Milan, Italy
关键词
Dyslipidaemia; Cholesterol; Triglycerides; Treatment; Cardiovascular diseases; Guidelines; CORONARY-HEART-DISEASE; DENSITY-LIPOPROTEIN CHOLESTEROL; CARDIOVASCULAR RISK-FACTORS; HIGH-DOSE ATORVASTATIN; POLYUNSATURATED FATTY-ACIDS; TYPE-2; DIABETES-MELLITUS; EXTENDED-RELEASE NIACIN; STATIN-TREATED PATIENTS; LIPID-LOWERING THERAPY; HIV-INFECTED PATIENTS;
D O I
10.1093/eurheartj/ehr158
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
[No abstract available]
引用
收藏
页码:1769 / 1818
页数:50
相关论文
共 224 条
  • [31] Byington RP, 2001, CIRCULATION, V103, P387
  • [32] Statins and fibrates for the treatment of hyperlipidaemia in HIV-infected patients receiving HAART
    Calza, L
    Manfredi, R
    Chiodo, F
    [J]. AIDS, 2003, 17 (06) : 851 - 859
  • [33] Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the coronary drug project)
    Canner, PL
    Furberg, CD
    Terrin, ML
    McGovern, ME
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 2005, 95 (02) : 254 - 257
  • [34] 15 YEAR MORTALITY IN CORONARY DRUG PROJECT PATIENTS - LONG-TERM BENEFIT WITH NIACIN
    CANNER, PL
    BERGE, KG
    WENGER, NK
    STAMLER, J
    FRIEDMAN, L
    PRINEAS, RJ
    FRIEDEWALD, W
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1986, 8 (06) : 1245 - 1255
  • [35] Perspectives on low-density lipoprotein cholesterol goal achievement
    Catapano, Alberico L.
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2009, 25 (02) : 431 - 447
  • [36] Niacin and fibrates in atherogenic dyslipidemia: Pharmacotherapy to reduce cardiovascular risk
    Chapman, M. John
    Redfern, Jan S.
    McGovern, Mark E.
    Giral, Philippe
    [J]. PHARMACOLOGY & THERAPEUTICS, 2010, 126 (03) : 314 - 345
  • [37] Targets of Statin Therapy: LDL Cholesterol, Non-HDL Cholesterol, and Apoliproprotein B in Type 2 Diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS)
    Charlton-Menys, Valentine
    Betteridge, D. John
    Colhoun, Helen
    Fuller, John
    France, Michael
    Hitman, Graham A.
    Livingstone, Shona J.
    Neil, H. Andrew W.
    Newman, Connie B.
    Szarek, Michael
    DeMicco, David A.
    Durrington, Paul N.
    [J]. CLINICAL CHEMISTRY, 2009, 55 (03) : 473 - 480
  • [38] Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
    Cleeman, JI
    Grundy, SM
    Becker, D
    Clark, LT
    Cooper, RS
    Denke, MA
    Howard, WJ
    Hunninghake, DB
    Illingworth, DR
    Luepker, RV
    McBride, P
    McKenney, JM
    Pasternak, RC
    Stone, NJ
    Van Horn, L
    Brewer, HB
    Ernst, ND
    Gordon, D
    Levy, D
    Rifkind, B
    Rossouw, JE
    Savage, P
    Haffner, SM
    Orloff, DG
    Proschan, MA
    Schwartz, JS
    Sempos, CT
    Shero, ST
    Murray, EZ
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19): : 2486 - 2497
  • [39] Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial
    Colhoun, HM
    Betteridge, DJ
    Durrington, PN
    Hitman, GA
    Neil, HAW
    Livingstone, SJ
    Thomason, MJ
    Mackness, MI
    Charlton-Menys, V
    Fuller, JH
    [J]. LANCET, 2004, 364 (9435) : 685 - 696
  • [40] Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3